| Rheumatoid arthritis | |
|---|---|
| Patients with BT | Extended interval |
| Adalimumab: 62 patients | 10 patients (16.1%) |
| Etanercept: 53 patients | 5 patients (9.5%) |
| Etanercept (cost per unit: 236,805€) | ||||
|---|---|---|---|---|
| Posology | Cost/patient/year | Incremental cost | Number of patients with extended interval | Annual savings |
| Etanercept 50 mg/7 days (standard) | €12,313.86 | |||
| Etanercept 50 mg/10 days | €8,524.98 | − €3,788.88 | 2 | €7,577.76 |
| Etanercept 50 mg/14 days | €6,156.93 | − €6,140.35 | 3 | €18,470.79 |
| Adalimumab (cost per unit: 514,145€) | ||||
|---|---|---|---|---|
| Posology | Cost/patient/year | Incremental cost | Number of patients with extended interval | Annual savings |
| Adalimumab 40 mg/14 days (standard) | €13,567.77 | |||
| Adalimumab 40 mg/21 days | €8,946.13 | − €4,621.64 | 6 | €27,729.84 |
| STOP upon prolonged remission of the disease | €13,567.77 | − €13,567.77 | 4 | €54,271.08 |